ENTITY

Alzinova (ALZ SS)

15
Analysis
Health Care • Sweden
Alzinova AB is a Swedish clinical-stage biopharma company that develops immunotherapies for the treatment of Alzheimer's disease. Its lead product candidate is ALZ-101, a therapeutic vaccine for Alzheimer's that has completed a phase 1b study. The company is also developing ALZ-201, a monoclonal antibody that targets and neutralizes the neurotoxic forms of the peptide Aß42, known as oligomers, which are considered a primary cause of Alzheimer's disease.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x